Stay updated on aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial

Sign up to get notified when there's something new on the aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    7 days ago
    Change Detected
    Summary
    The record now presents details of the completed ADRISK phase 2 trial, including its pembrolizumab treatment comparison, eligibility criteria, study locations, and outcome measures. It also includes study history and a publication reporting initial trial data.
    Difference
    48%
    Check dated 2026-11-08T00:49:29.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0; the study page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T18:53:41.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    A notice appears at the top of the page announcing NIH website updates and explaining that some content may use “Super Intelligence” in place of “Artificial Intelligence” during a transition.
    Difference
    1%
    Check dated 2026-10-24T20:12:02.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T20:55:25.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The site revision label in the footer changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-10T21:50:58.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    A 403 Forbidden page is now shown, replacing the detailed study information and leaving a minimal header and navigation. The page presents a generic access-denied view rather than the original ClinicalTrials.gov study record contents.
    Difference
    17%
    Check dated 2026-09-19T20:35:21.000Z thumbnail image

Stay in the know with updates to aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial page.